A Meta-Analysis of Randomized Trials for the Treatment of Nonalcoholic Fatty Liver Disease

Hepatology - Tập 52 Số 1 - Trang 79-104 - 2010
Giovanni Musso1, Roberto Gambino2, Maurizio Cassader2, Gianfranco Pagano2
1Gradenigo Hospital, Turin, Italy
2Department of Internal Medicine, University of Turin, Italy

Tóm tắt

Nonalcoholic fatty liver disease (NAFLD) encompasses a histological spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). NAFLD carries a higher risk of cardio-metabolic and liver-related complications, the latter being confined to NASH and demanding specific treatment. We assessed the efficacy of proposed treatments for NAFLD/NASH by reviewing reports of randomized controlled trials (RCTs) on online databases and national and international meeting abstracts through January 2010. Primary outcome measure was histological improvement; secondary outcome was biochemical improvement; improvement in radiological steatosis was also evaluated. Two reviewers extracted articles using predefined quality indicators, independently and in duplicate. Main outcomes of randomized controlled trials (RCTs) were pooled using random-effects or fixed-effects models. Publication bias was assessed by funnel plots. Forty-nine RCTs (30 in NASH) were included: 23 RCTs (22 in NASH, 1 in NAFLD) had post-treatment histology. Most RCTs were small and did not exceed 1-year duration. Weight loss, thiazolidinediones (especially pioglitazone), and antioxidants were most extensively evaluated. Weight loss was safe and dose-dependently improved histological disease activity in NASH, but more than 50% of patients failed to achieve target weight loss. Thiazolidinediones improved steatosis and inflammation but yielded significant weight gain. RCTs with antioxidants yielded conflicting results and were heterogeneous with respect to type and dose of drug, duration, implementation of lifestyle intervention. Among the other agents, pentoxifylline, telmisartan and L-carnitine improved liver histology in at least 1 RCT in NASH; polyunsaturated fatty acid (PUFA) ameliorated biochemical and radiological markers of NAFLD. Other approaches yielded negative results. Conclusion: Well-designed RCTs of adequate size and duration, with histological endpoints, are needed to assess long-term safety and efficacy of proposed treatments on patient-oriented clinical outcomes. Hepatology 2010

Từ khóa


Tài liệu tham khảo

Promrat, 2010, Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis., Hepatology, 51, 121129, 10.1002/hep.23276

Nobili, 2008, Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial., Hepatology, 48, 119128, 10.1002/hep.22336

Harrison, 2009, Orlistat for overweight subjects with nonalcoholic steatohepatitis (NASH): a randomized prospective trial., Hepatology, 49, 8086, 10.1002/hep.22575

ZelberSagi, 2006, A doubleblind randomized placebocontrolled trial of orlistat for the treatment of nonalcoholic fatty liver disease., Clin Gastroenterol Hepatol, 4, 639644

Johnson, 2009, Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss., Hepatology, 50, 11051112, 10.1002/hep.23129

2009, George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with nonalcoholic fatty liver., Hepatology, 50, 6876

Kirk, 2009, Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction., Gastroenterology, 136, 15521560, 10.1053/j.gastro.2009.01.048

Sanyal, 2004, A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis., Clin Gastroenterol Hepatol, 2, 11071115, 10.1016/S1542-3565(04)00457-4

Belfort, 2006, A placebocontrolled trial of pioglitazone in subjects with nonalcoholic steatohepatitis., N Engl J Med, 355, 22972307, 10.1056/NEJMoa060326

Aithal, 2008, Randomized, placebocontrolled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis., Gastroenterology, 135, 11761184, 10.1053/j.gastro.2008.06.047

Ratziu, 2008, Rosiglitazone for nonalcoholic steatohepatitis: oneyear results of the randomized placebocontrolled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial., Gastroenterology, 135, 100110, 10.1053/j.gastro.2008.03.078

Idilman, 2008, Clinical trial: insulinsensitizing agents may reduce consequences of insulin resistance in individuals with nonalcoholic steatohepatitis., Aliment Pharmacol Ther, 28, 200208, 10.1111/j.1365-2036.2008.03723.x

Gastaldelli, 2009, Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of NASH patients., Hepatology, 50, 10871093, 10.1002/hep.23116

Lutchman, 2007, The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis., Hepatology, 46, 424429, 10.1002/hep.21661

Argo, 2009, Thiazolidinediones in NASH: sustained benefit after drug discontinuation?, J Clin Gastroenterol, 43, 565568, 10.1097/MCG.0b013e31818f4fc2

Ratziu, 2010, Longterm efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the FLIRT2 extension trial., Hepatology, 51, 445453, 10.1002/hep.23270

Chalasani, 2009, Pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis: PIVENS trial design., Contemp Clin Trials, 30, 8896, 10.1016/j.cct.2008.09.003

Sanyal, 2009, A randomized controlled trial of pioglitazone or vitamin E for nonalcoholic steatohepatitis (PIVENS)., Hepatology, 50, 1A

Uygun, 2004, Metformin in the treatment of patients with nonalcoholic steatohepatitis., Aliment Pharmacol Ther, 19, 537544, 10.1111/j.1365-2036.2004.01888.x

Haukeland, 2009, Metformin in patients with nonalcoholic fatty liver disease: a randomized, controlled trial., Scandinavian Journal of Gastroenterology, 44, 853860, 10.1080/00365520902845268

Shields, 2009, The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial., Ther Adv Gastroenterology, 2, 157163

Bugianesi, 2005, A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease., Am J Gastroenterol, 100, 10821090, 10.1111/j.1572-0241.2005.41583.x

Nar, 2009, The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease., Acta Diabetol, 46, 113118, 10.1007/s00592-008-0067-2

Torres, 2009, The effect of 48 weeks of rosiglitazone alone versus combination rosiglitazone and metformin (Avandamet) versus combination rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis (NASH): a openlabel prospective randomised clinical trial Abstract., Hepatology, 50, 390A

Omer, 2010, Efficacy of insulinsensitizing agents in nonalcoholic fatty liver disease., Eur J Gastroenterol Hepatol, 22, 1823, 10.1097/MEG.0b013e32832e2baf

Tiikkainen, 2004, Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes., Diabetes, 53, 21692176, 10.2337/diabetes.53.8.2169

Fabbrini, 2009, Methods for assessing intrahepatic fat content and steatosis., Curr Opin Clin Nutr Metab Care, 12, 474481, 10.1097/MCO.0b013e32832eb587

Spadaro, 2008, Effects of n3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease., Dig Liv Dis, 40, 194199, 10.1016/j.dld.2007.10.003

Zhu, 2008, Effects of n3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia., World J Gastroenterol, 14, 63956400, 10.3748/wjg.14.6395

Cussons, 2009, Omega3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy., J Clin Endocrinol Metab, 94, 38423848, 10.1210/jc.2009-0870

Basaranoglu, 1999, A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis., J Hepatol, 31, 384, 10.1016/S0168-8278(99)80243-8

De Denus, 2004, Statins and liver toxicity: a metaanalysis., Pharmacotherapy, 24, 584591, 10.1592/phco.24.6.584.34738

Browning, 2006, Statins and hepatic steatosis: perspectives from the Dallas Heart Study., Hepatology, 44, 466471, 10.1002/hep.21248

Cohen, 2006, An assessment of statin safety by hepatologists., Am J Cardiol, 97, 77C81C, 10.1016/j.amjcard.2005.12.014

Nelson, 2009, A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebocontrolled trial., J Clin Gastroenterol, 43, 990994, 10.1097/MCG.0b013e31819c392e

Athyros, 2006, Effect of multifactorial treatment on nonalcoholic fatty liver disease in metabolic syndrome: a randomised study., Curr Med Res Opin, 22, 873883, 10.1185/030079906X104696

Ekstedt, 2007, Statins in nonalcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological followup study., J Hepatol, 47, 135141, 10.1016/j.jhep.2007.02.013

Merat, 2003, Probucol in the treatment of nonalcoholic steatohepatitis: a doubleblind randomized controlled study., J Hepatol, 38, 414418, 10.1016/S0168-8278(02)00441-5

Lindor, 2004, Ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: results of a randomized trial., Hepatology, 39, 770778, 10.1002/hep.20092

Dufour, 2006, Randomized placebocontrolled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis., Clin Gastroenterol Hepatol, 4, 15371543, 10.1016/j.cgh.2006.09.025

Santos, 2003, A randomized doubleblind study of the shorttime treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid., Braz J Med Biol Res, 36, 723729, 10.1590/S0100-879X2003000600007

MendezSanchez, 2004, Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease: a doubleblind, placebocontrolled trial., Ann Hepatol, 3, 108112

Ersoz, 2005, Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment., Turk J Gastroenterol, 16, 124128

Kugelmas, 2003, Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E., Hepatology, 38, 413419, 10.1053/jhep.2003.50316

Rui, 2001, The clinical comparison of reduced glutathione and DaiNingPlan in the treatment of nonalcoholic steatohepatitis., Chinese General Practice, 4, 269270

Harrison, 2003, Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis., Am J Gastroenterol, 98, 24852490, 10.1111/j.1572-0241.2003.08699.x

Abdelmalek, 2009, Betaine for nonalcoholic fatty liver disease: results of a randomized placebocontrolled trial., Hepatology, 50, 18181826, 10.1002/hep.23239

Pamuk, 2003, Nacetylcysteine in the treatment of nonalcoholic steatohepatitis., J Gastroenterol Hepatol, 18, 12201221

Miglio, 2000, Efficacy and safety of oral betaine glucuronate in nonalcoholic steatohepatitis: a doubleblind, randomized, parallel group, placebocontrolled prospective clinical study., Arzneimittelforschung, 50, 722727

Vilar Gomez, 2009, Clinical trial: Viusid(R) in combination with diet and exercise in patients with nonalcoholic fatty liver disease., Aliment Pharmacol Ther, 30, 9991009, 10.1111/j.1365-2036.2009.04122.x

Miller, 2005, Metaanalysis: highdosage vitamin E supplementation may increase allcause mortality., Ann Intern Med, 142, 3746, 10.7326/0003-4819-142-1-200501040-00110

Lee, 2008, A randomized controlled pilot study of pentoxifylline in patients with nonalcoholic steatohepatitis (NASH)., Hepatol Int, 2, 196201, 10.1007/s12072-008-9058-1

Rinella, 2009, Pentoxifylline improves ALT and histology in patients with NASH: a doubleblind placebo controlled trial., Gastroenterology, 136, 10.1016/S0016-5085(09)60398-X

Georgescu, 2009, Angiotensinreceptor blockers as therapy for mildtomoderate hypertensionassociated nonalcoholic steatohepatitis., World J Gastroenterol, 15, 942954, 10.3748/wjg.15.942

Despres, 2009, Effect of rimonabant on the hightriglyceridelowHDLcholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIOLipids trial., Arterioscler Thromb Vasc Biol, 29, 416423, 10.1161/ATVBAHA.108.176362

Mummadi, 2008, Effect of bariatric surgery on nonalcoholic fatty liver disease (NAFLD): systematic review and metaanalysis., Clin Gastroenterol Hepatol, 6, 13961402, 10.1016/j.cgh.2008.08.012

Mattar, 2005, Surgicallyinduced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome., Ann Surg, 242, 610620, 10.1097/01.sla.0000179652.07502.3f

Mathurin, 2009, A prospective study of the longterm effects of bariatric surgery on liver injury in patients without advanced disease., Gastroenterology, 137, 532540, 10.1053/j.gastro.2009.04.052

Luyckx Fh, Desaive, 1998, Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty., Int J Obes Relat Metab Disord, 22, 222226

Arase, 2009, Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease., J Gastroenterol, 44, 10641070, 10.1007/s00535-009-0091-1

Wadden, 2006, The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it., Obesity, 14, 737752

Argo, 2009, Systematic review of risk factors for fibrosis progression in nonalcoholic steatohepatitis., J Hepatol, 51, 371379, 10.1016/j.jhep.2009.03.019

Thông tin
Thông tin xuất bản

Hepatology

Tập 52 Số 1

79-104

Thông tin tác giả